The current study aims to evaluate the therapeutic efficacy of combined treatment with donepezil and MC therapy, focusing on their potential to activate PI3K–AKT–AMPK survival signaling, inhibit GSK-3β activity, and modulate JAK2/3-related immune signaling, ultimately inducing synergistic neuroprotection in AD. This evidence concerns the gene JAK2 and Alzheimer disease.